SEQIRUS UK LIMITED

Location

Founded

2015-05-29

Website

https://www.seqirus.co.uk

Risk Signals

39 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Offices of Holding Companies, Not Elsewhere Classified, Business Services, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

Public Health Crisis Response (72) Corporate Deals (26) Inter-Organizational Collaborations (23) EU Political Updates (16) Business Agreements (14) Government Policy Developments (13) Regulatory Decisions (9) Corporate Awards and Recognitions (9) Financial Reporting (8) Earnings Reports & Warnings (7) Access and Affordability Initiatives (6) Acquisition Announcements (6) New Product Release (6) Procurement Contracts (6) Stock Market Events (4) Environmental Assessments (3) Government Relations (3) Data Privacy Regulations (3) Employee Safety & Health (3) Market Trends (2) Human Rights Advocacy (2) Business Resilience Planning (1) Investment Strategies (1) Startup Launches (1) Cybersecurity Breaches (1) Biodiversity Conservation (1) Artificial Intelligence Developments (1) Regulatory Updates (1) Renewable Energy Innovations (1) Executive Leadership Changes (1)

Recent Articles about SEQIRUS UK LIMITED

Live alerts from global media, monitored by Business Radar

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

2025-03-17 (businesswire.com)

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of inf...

Read more
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

2024-10-30 (stocktitan.net)

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

Amarin reports mixed Q3 results: 36% revenue decline to $42.3M, but maintains $306M cash position. European VAZKEPA sales surge 19% while U.S. sales face headwinds. See detailed analysis of pharma giant's performance.

Read more

Never miss a headline about SEQIRUS UK LIMITED

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages